Multimedia Platforms is the only publicly-traded pure play multimedia company targeting the LGBT demographic. The Company’s potential target market includes 400 million individuals worldwide that identify as lesbian, gay, bisexual, or transgender represents an estimated $3 trillion in buying power.

If future test results affirm the data derived from recent studies, the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® diabetes treatment platform could emerge as the treatment of choice for this disease.

With the interest rate concerns behind us, it is time to profile a stock that has such profoundly strong milestones in ahead in 2016 that we believe it will jump from $1 to $5.

Today we are introducing a new idea---a ground floor opportunity, really. One of the fastest growing industries is the mobile gaming market and Pocket Games, Inc. (OTC – PKGM) has a targeted acquisition strategy and very clever approach which has already begun to bear fruit.

PharmaCyte’s novel approach could emerge as one of the most effective and diverse cancer treatment platforms in the market for solid tumors of all kinds and could be worth billions of dollars.

The market may be flirting with year highs but this incredibly undervalued stock has not yet made its move, which we think could occur before year-end. Here’s why, as outlined in a new sponsored research update:

Recent and pending events infer that the road to approval and marketing of Pharmacyte's flagship pancreatic cancer treatment has been dramatically shortened, potentially leading to a banner year 2016 for PharmaCyte shareholders.

This low valuation medical device company is set to transform its segment of the $3 billion electrophysiology (EP) marketplace. EP studies are used in conjunction with cardiac ablation procedures for patients suffering from atrial fibrillation (AF) and other conditions. The Company’s flagship platform fulfills an unmet need by enhancing the efficacy and diagnostic value of EP studies. Moreover, it reduces the frequency of and the time it takes to complete EP studies used in cardiac ablation procedures.

PMCB's approach to diabetes therapy could ultimately become a treatment that has clear advantages over current therapies used for Type 1 diabetes, and could potentially replace them.

Last week was an incredible week for PharmaCyte Biotech (OTC – PMCB), which prompted us to issue a new research update. Major industry and company news released last week should take investor sentiment and the stock to a new level regarding the potential and timing of FDA approval for PharmaCyte’s pancreatic cancer treatment for patients with locally advanced pancreatic cancer.